Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08DFX
|
|||
| Former ID |
DCL001169
|
|||
| Drug Name |
Canagliflozin
|
|||
| Synonyms |
842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Approved | [1], [2], [3], [4] | |
| Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 3 | [4] | ||
| Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 2 | [5], [4] | ||
| Company |
Johnson & Johnson
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H25FO5S
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
|
|||
| InChIKey |
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
|
|||
| CAS Number |
CAS 842133-18-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
49811874, 57127075, 125299338, 134358471, 135267033, 136023439, 136340353, 136367529, 136368011, 141631822, 144115779, 144224573, 152159581, 152258221, 160647057, 160695863, 160865968, 162011557, 162169318, 162205127, 164837687, 170500828, 172918748, 174530759, 175266021, 175427146, 178101303, 185964359, 196373210, 198993774, 202567714, 211535181, 223258907, 223471388, 223617458, 223705166, 224378424, 226521104, 248537044, 249737173, 250163176, 252109951, 252215091
|
|||
| ChEBI ID |
CHEBI:73274
|
|||
| ADReCS Drug ID | BADD_D00344 | |||
| SuperDrug ATC ID |
A10BX11
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Target Info | Modulator | [2], [3], [6] |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4582). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 2014 Oct;63(10):1296-303. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.World J Diabetes.2014 Jun 15;5(3):399-406. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.